ArticleCureus2025
Description and Control Levels of Hypertriglyceridemia Among Patients Attending Family Medicine Clinics in Riyadh, Saudi Arabia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Hypertriglyceridemia (HTG) is a prevalent lipid disorder associated with an increased risk of cardiovascular disease (CVD) and acute pancreatitis. Effective management of HTG remains a significant public health concern, particularly in Saudi Arabia, where prevalence rates vary widely. This study aims to assess the level of control of HTG among patients attending family medicine clinics in Riyadh, Saudi Arabia, and to evaluate the effectiveness of different treatment modalities. Methods A cross-sectional chart review was conducted on patients from the National Guard Health Affairs Primary Health Care Centers in Riyadh between January 1, 2019, and December 31, 2022. Adults (≥18 years) with triglyceride levels ≥1.7 mmol/L and at least two visits during the study period were included. Patients with renal or liver disease and certain metabolic conditions were excluded. Data were extracted from electronic medical records, including demographics, comorbidities, lipid profiles, and treatment regimens. Statistical analysis was performed to assess triglyceride level reductions and treatment efficacy. Results Among 415 patients (median age 62 years), 245 (59%) were female and 170 (41%) were male. Triglyceride levels significantly decreased from a median of 2.90 mmol/L to 1.70 mmol/L post-treatment (p < 0.001). Statins, particularly simvastatin 10 mg, showed a significant effect on triglyceride reduction (p = 0.049). Lifestyle modifications and marital status were also associated with improved outcomes. Conclusion HTG management in primary care settings showed promising results, with significant triglyceride reductions. Further studies should explore adherence to lifestyle interventions and additional pharmacological options to enhance HTG control and reduce CVD risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.